SK152998A3 - Racemic separation of ketamine - Google Patents
Racemic separation of ketamine Download PDFInfo
- Publication number
- SK152998A3 SK152998A3 SK1529-98A SK152998A SK152998A3 SK 152998 A3 SK152998 A3 SK 152998A3 SK 152998 A SK152998 A SK 152998A SK 152998 A3 SK152998 A3 SK 152998A3
- Authority
- SK
- Slovakia
- Prior art keywords
- water
- chlorophenyl
- methylaminocyclohexanone
- mixture
- process according
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
- C07C225/20—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C221/00—Preparation of compounds containing amino groups and doubly-bound oxygen atoms bound to the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Indole Compounds (AREA)
- Pyrrole Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Farmakologické výskumy doložili výrazné kvalitatívne a kvantitatívne rozdiely medzi R- a S-ketamínovými enantiomérmi. Ako preklinická tak tiež klinická štúdia vymedzujú S-ketamín ako vždy lepší ako antipody alebo racemát. Z tohto hladiska je potrebné dávať prednosť výlučnému terapeutickému použitiu enantioméru a oddelovat racemát. V nasledujúcom texte je vždy mienený S-enantiomér, ktorý je v podobe soli v konfigurácii S-(+)a v podobe čistej zásady v S-(-)-konfigurácii.Pharmacological studies have demonstrated significant qualitative and quantitative differences between the R- and S-ketamine enantiomers. Both preclinical and clinical studies define S-ketamine as always superior to antipodes or racemate. In this respect, the exclusive therapeutic use of the enantiomer should be preferred and the racemate separated. In the following, the S-enantiomer is always meant to be in the form of a salt in the S - (+) configuration and a pure base in the S - (-) configuration.
Z nemeckej zverejnenej prihlášky vynálezu číslo DE-A2 062 620 je známy spôsob štiepenia racemického 2-(o-chlórfenyl)-2-metylaminocyklohexanónu, pri ktorom sa necháva reagovať racemický 2-(o-chlórfenyl)-2-metylaminocyklohexanón pri použití enantiomérnej formy kyseliny vínnej v rozpúšťadlovej zmesi obsahujúcej vodu a acetón, vytvorená sol kyseliny vínnej sa izoluje filtráciou a následným dvojnásobným prekryštalizovaním z acetonitrilu a potom sa jeden izomér zo soli s vínnou kyselinou uvolňuje pôsobením alkálie. Nedostatkom tohto spôsobu sú však malé výťažky, používanie jedovatých rozpúšťadiel, nečisté produkty a nutnosť vykonávať početné výrobné kroky.DE-A2 062 620 discloses a process for resolution of racemic 2- (o-chlorophenyl) -2-methylaminocyclohexanone by reacting racemic 2- (o-chlorophenyl) -2-methylaminocyclohexanone using the enantiomeric form of the acid The tartaric acid salt formed in the solvent mixture containing water and acetone is isolated by filtration and then recrystallized twice from acetonitrile and then one isomer is liberated from the tartaric acid salt by treatment with alkali. However, the disadvantages of this process are low yields, the use of poisonous solvents, impure products and the need for numerous production steps.
Preto je úlohou vynálezu vyvinúť zlepšený spôsob štiepenia racemického 2-(o-chlórfenyl)-2-metylaminocyklohexanónu, ktorý by bol bez hore uvedených nedostatkov.It is therefore an object of the present invention to provide an improved process for the resolution of racemic 2- (o-chlorophenyl) -2-methylaminocyclohexanone which is free from the above drawbacks.
Podstata vynálezuSUMMARY OF THE INVENTION
Spôsob štiepenia racemického 2-(o-chlórfenyl)-2-metylaminocyklohexanónu vzorca IProcess for resolution of racemic 2- (o-chlorophenyl) -2-methylaminocyclohexanone of formula I
kde * vyznačuje asymetrický atóm uhlíka, pri ktorom sawherein * denotes an asymmetric carbon atom in which
1) necháva reagovať racemický 2-(o-chlórfenyl)-2-metylaminocyklohexanón s enantiomérnou formou kyseliny vínnej,1) reacting racemic 2- (o-chlorophenyl) -2-methylaminocyclohexanone with the enantiomeric form of tartaric acid,
2) izoluje sa vytvorená sol 2-(o-chlórfenyl)-2-metylaminocyklohexanónu s kyselinou vínnou a2) isolating the formed tartaric acid salt of 2- (o-chlorophenyl) -2-methylaminocyclohexanone; and
3) izolovaná sol 2-(o-chlórfenyl)-2-metylaminocyklohexanónu s kyselinou vínnou sa necháva reagovať s alkáliou, pričom sa izoluje izomér 2-(o-chlórfenyl)-2-metylaminocyklohexanónu, spočíva podlá vynálezu v tom, že sa stupeň 1 a 2 vykonáva vo vode alebo v zmesi vody a acetónu a/alebo izopropanolu.3) The isolated tartaric acid salt of 2- (o-chlorophenyl) -2-methylaminocyclohexanone is reacted with an alkali to isolate the 2- (o-chlorophenyl) -2-methylaminocyclohexanone isomer according to the invention in that step 1 and 2 is carried out in water or in a mixture of water and acetone and / or isopropanol.
Štiepenie racemátu R,S-ketamínu pri použití L-(+)-vínnej kyseliny (stupeň 1, 2)Resolution of R, S-ketamine racemate using L - (+) - tartaric acid (step 1, 2)
R,S-ketamín mol. hmotn. 237 g/molR, S-ketamine mol. weight. 237 g / mol
L-(+)-vínna k mol. hmotn. 150,1 g/molL - (+) - wine to mol. weight. 150.1 g / mol
S-(+)-ketamínvínan mol. hmotn.S - (+) - ketamine tartrate mol. weight.
387 g/mol387 g / mol
Príprava S-(-)-ketamínu (stupeň 3)Preparation of S - (-) - Ketamine (Grade 3)
• C«H6O6 * 2 NaOH• C 6 H 6 O 6 * 2 NaOH
S-(+)-ketamínvínan mol.S - (+) - ketamine tartrate mol.
hmotn.387 g/mol378 g / mol
+ NajC^HjOe + 2HjO + NaClH2O6 + 2H2O
S-(-)-ketamín mol. hmotn.S - (-) - ketamine mol. weight.
237,7 g/mol237.7 g / mol
Vytváranie s-(+)-ketamín HCIFormation with - (+) - Ketamine HCl
S-(-)-ketamín mol. hmotn. 237,7 g/molS - (-) - ketamine mol. weight. 237.7 g / mol
HCI plynný HCI mol. hmotn. 37,5 g/molHCl gaseous HCl mol. weight. 37.5 g / mol
S-(+)-ketamín HCI mol. hmotn.S - (+) - ketamine HCl mol. weight.
274,2 g/mol274.2 g / mol
Pri spôsobu podía vynálezu sa racemický 2-(o-chlórfenyl)2-metylaminocyklohexanón v prvom stupni necháva reagovať s enantiomérnou formou kyseliny vínnej za vytvorenia soli kyseliny vínnej s 2-(o-chlórfenyl)-2-metylaminocyklohexanónom.In the process of the invention, racemic 2- (o-chlorophenyl) 2-methylaminocyclohexanone is first reacted with an enantiomeric form of tartaric acid to form a tartaric acid salt with 2- (o-chlorophenyl) -2-methylaminocyclohexanone.
Ako rozpúšťadlá sa pri tejto reakcii používa voda alebo zmes vody a organického rozpúšťadla zvoleného zo súboru zahŕňajúceho alkohol s 1 až 6 atómami uhlíka s priamym alebo s rozvetveným reťazcom a/alebo ketón, ester alebo éter, s výhodou izopropanol a/alebo acetón. S výhodou sa používa voda alebo zmes vody a izopropanolu alebo zmes vody a acetónu. V prípade použitia zmesi vody a izopropanolu je pomer voda:izopropanol s výhodou 1,5:1. Pri použití zmesi vody a acetónu je pomer voda:acetón s výhodou 1:0,33 až 5,0, najmä 1:3. Ako iné, rovnako do úvahy prichádzajúce rozpúšťadlá, sa príkladne uvádzajú metanol, etanol, n-propanol, butanol, terc.-butanol, pentanol, hexanol, metyletylketón, dimetylketón, propylmetylketón a/alebo etylacetát.The solvents used in this reaction are water or a mixture of water and an organic solvent selected from the group consisting of a straight-chain or branched C1-C6 alcohol and / or a ketone, ester or ether, preferably isopropanol and / or acetone. Preferably, water or a mixture of water and isopropanol or a mixture of water and acetone is used. When using a mixture of water and isopropanol, the water: isopropanol ratio is preferably 1.5: 1. When using a mixture of water and acetone, the water: acetone ratio is preferably 1: 0.33 to 5.0, especially 1: 3. Examples of other solvents which may be considered are methanol, ethanol, n-propanol, butanol, tert-butanol, pentanol, hexanol, methyl ethyl ketone, dimethyl ketone, propyl methyl ketone and / or ethyl acetate.
V ďalšom stupni sa vytvorená sol kyseliny vínnej s 2-(ochlórfenyl)-2-metylaminocyklohexanónom izoluje. Táto izolácia sa s výhodou vykonáva filtráciou. V prípade použitia zmesi vody a acetónu v pomere 1:10 až 20 sa vytvorená sol s kyselinou vínnou s výhodou po izolácii necháva prekryštalizovať na ďalšie obohatenie izomérnym 2-(o-chlórfenyl)-2-metylaminocyklo hexánonom obohateného vínanu pri použití zmesi vody a acetónu v stupni 1. Pri použití vody alebo zmesi vody a izopropanolu alebo zmesi vody a acetónu v pomere 1:0,33 až 5,0 ako rozpúšťadla je možné upustiť od prekryštalizovania izolovanej soli kyseliny vínnej s 2-(o-chlórfenyl)-2-metylaminocyklohexanónom.In the next step, the tartaric acid salt formed with 2- (chlorophenyl) -2-methylaminocyclohexanone is isolated. This isolation is preferably carried out by filtration. In the case of using a 1:10 to 20 water / acetone mixture, the tartaric acid salt formed, preferably after isolation, is recrystallized for further enrichment with isomeric 2- (o-chlorophenyl) -2-methylaminocyclo-hexanone-enriched tartrate using a water / acetone mixture In step 1. When using water or a mixture of water and isopropanol or a mixture of water and acetone in a ratio of 1: 0.33 to 5.0 as solvent, recrystallization of the isolated tartaric acid salt with 2- (o-chlorophenyl) -2- methylaminocyclohexanone.
V treťom stupni sa podlá stupňa 2 získaný vínan 2-(ochlórfenyl)-2-metylaminocyklohexanónu necháva reagovať s alkáliou, pričom sa získa kryštalický produkt. Ide o izomérne čistý 2-(o-chlórfenyl)-2-metylaminocyklohexanón. Tento 2-(ochlórfenyl)-2-metylaminocyklohexanón sa získa napríklad odfiltrovaním.In step 3, the 2- (chlorophenyl) -2-methylaminocyclohexanone tartrate obtained in step 2 is reacted with an alkali to give a crystalline product. It is isomerically pure 2- (o-chlorophenyl) -2-methylaminocyclohexanone. This 2- (chlorophenyl) -2-methylaminocyclohexanone is obtained, for example, by filtration.
Následne sa izomérne čistý ketamín môže kyselinou chlorovodíkovou premieňať na zodpovedajúci hydrochlorid.Subsequently, the isomerically pure ketamine can be converted to the corresponding hydrochloride by hydrochloric acid.
Vynález objasňujú, žiadnym spôsobom však neobmedzujú nasledujúce príklady praktického rozpracovania.The invention is illustrated by the following non-limiting examples.
Príklady rozpracovania vynálezuDETAILED DESCRIPTION OF THE INVENTION
Príklad 1Example 1
Rozpustí sa 50 g (0,21 mol) R,S-ketamínu za teploty varu v 613 ml acetónu a zmieša sa s 31,5 g (0,21 mol) L-( + )-vínnej kyseliny. Na získanie číreho roztoku sa za teploty varu pridá 40 ml vody a následne sa číry roztok za horúca odfiltruje. Po pridaní očkovacích kryštálov, získaných predbežne pri uskutočnení skúšky v malom meradle, sa zmes ako celok nechá za miešania ochladiť na teplotu miestnosti. Nechá sa stáť cez noc, vytvorené kryštály sa odsajú a sušia sa v sušičke s núteným obehom vzduchu (najskôr pri teplote miestnosti, neskoršie pri teplote 50 až 60°C).Dissolve 50 g (0.21 mol) of R, S-ketamine at boiling point in 613 ml of acetone and mix with 31.5 g (0.21 mol) of L- (+) - tartaric acid. To obtain a clear solution, 40 ml of water are added at boiling point, and then the clear solution is filtered while hot. After addition of the seed crystals obtained previously in the small scale test, the mixture as a whole is allowed to cool to room temperature with stirring. After standing overnight, the crystals formed are aspirated and dried in a forced-air dryer (first at room temperature, later at 50-60 ° C).
Výťažok (vínan): 64,8 gYield (tartrate): 64.8 g
Teplota topenia 161°C [_]D + 26,1’ (c = 2/H2O)Melting point 161 ° C [_] D + 26.1 '(c = 2 / H 2 O)
Potom sa kryštalizát prekryštalizuje zo zmesi 1226 ml acetónu a 90 ml vody. Po ochladení na teplotu miestnosti a po štyrhodinovom miešaní sa kryštály odsajú a sušia sa v sušičke s núteným obehom vzduchu (najskôr pri teplote miestnosti, neskoršie pri teplote 50 až 60°C). Získa sa 38,8 g vínanu (95, 29 % teórie).The crystallizate is then recrystallized from a mixture of 1226 ml of acetone and 90 ml of water. After cooling to room temperature and stirring for four hours, the crystals are aspirated and dried in a forced-air dryer (first at room temperature, later at 50-60 ° C). Yield: 38.8 g (95.29% of theory).
Teplota topenia 175,3’C [_]D + 68,9’ (c = 2/H2O)Melting point 175.3 ° C [_] D + 68.9 '(c = 2 / H 2 O)
Uvoľnenie zásady sa vykonáva tak, že sa 38,8 g vínanu vyberie do 420 ml sodného lúhu a mieša sa s 540 ml éteru. Éterová fáza sa premyje vodou a potom nasýteným roztokom chloridu sodného. Organická fáza sa vysuší síranom sodným. Po filtrácii sa roztok zahustí do sucha na rotačnej odparke. získa sa kryštalický bezfarbý produkt. Výťažok (surová báza): 21,5 g, to je 86,0 % teórie.The liberation of the base is carried out by taking 38.8 g of tartrate into 420 ml of sodium hydroxide solution and stirring with 540 ml of ether. The ether phase is washed with water and then with saturated sodium chloride solution. The organic phase is dried over sodium sulfate. After filtration, the solution is concentrated to dryness using a rotary evaporator. a crystalline colorless product is obtained. Yield (crude base): 21.5 g, i.e. 86.0% of theory.
Teplota topenia 118,9’C (podľa literatúry 120 až 122'C) [_]D “ 55,8’ (c = 2/EtOH) (podľa literatúry [_]D - 56,35’)Melting point 118.9 ° C (according to literature 120-122 ° C) [_] D '55.8' (c = 2 / EtOH) (according to literature [_] D - 56.35 ')
Pre prípadné ďalšie čistenie sa surová báza môže prekryštalizovať z cyklohexánu. Za týmto účelom sa 10,75 g surovej zásady rozpustí za varu v 43 ml cyklohexánu. Číry roztok sa ochladzuje pomaly za miešania na teplotu približne 10’C a mieša sa približne počas jednej hodiny pri tejto teplote. Vzniknutý kryštalizát sa odsaje a suší sa až do dosiahnutia konštantnej hmotnosti. Výťažok (báza): 10,3 g, to je 82,4 % teórie.For further purification, the crude base can be recrystallized from cyclohexane. To this end, 10.75 g of crude base is dissolved in boiling in 43 ml of cyclohexane. The clear solution is cooled slowly with stirring to a temperature of about 10 ° C and stirred for about one hour at this temperature. The resulting crystallizate is filtered off with suction and dried until a constant weight is obtained. Yield (base): 10.3 g, that is 82.4% of theory.
Teplota topenia 120C (podľa literatúry 120 až 122°C) [_]D - 56,8’ (c = 2/EtOH) (podľa literatúry [_]D - 56,35”)Melting point 120C (according to literature 120 to 122 ° C) [_] D - 56.8 '(c = 2 / EtOH) (according to literature [_] D - 56.35 ”)
Príklad 2Example 2
Predloží sa 125 ml vody a pridá sa 31,5 g (0,21 mol) L(+)-vínnej kyseliny a 50 g (0,21 mol) R,S-ketamínu. Zmes sa za miešania zahrievaním udržuje na teplote 50 až 60”C až do získania číreho roztoku.125 ml of water are introduced and 31.5 g (0.21 mol) of L (+) - tartaric acid and 50 g (0.21 mol) of R, S-ketamine are added. The mixture is maintained under stirring at 50-60 ° C with stirring until a clear solution is obtained.
Po ochladení na teplotu miestnosti za miešania a dodatočnom miešaní cez noc sa vytvorené kryštály odsajú. Kryštalizát sa premyje najskôr 8 ml vody (s teplotou 1 až 6’C) a potom dvakrát vždy 20 ml acetónu.After cooling to room temperature with stirring and additional stirring overnight, the crystals formed are aspirated. The crystallizate is washed first with 8 ml of water (1-6 ° C) and then twice with 20 ml of acetone.
Sušením v sušičke s núteným obehom vzduchu (najskôr pri teplote miestnosti, neskoršie pri teplote 50 až 60’C) sa získa 31,79 g vínanu (78,23 % teórie).Drying in a forced-air dryer (first at room temperature, later at 50-60 ° C) yields 31.79 g of tartrate (78.23% of theory).
Príklad 3Example 3
Predloží sa 150 ml vody a pridá sa 39,8 g (0,27 mol) L(+)-vínnej kyseliny a 50 g (0,21 mol) R,S-ketamínu. Zmes sa za miešania zahrievaním udržuje na teplote 50 až 60”C až do získania číreho roztoku.150 ml of water are introduced and 39.8 g (0.27 mol) of L (+) - tartaric acid and 50 g (0.21 mol) of R, S-ketamine are added. The mixture is maintained under stirring at 50-60 ° C with stirring until a clear solution is obtained.
Po ochladení na teplotu miestnosti za miešania a dodatočnom miešaní cez noc sa vytvorené kryštály odsajú. Kryštalizát sa premyje najskôr 8 ml vody (s teplotou 1 až 6”C) a potom dvakrát vždy 20 ml acetónu.After cooling to room temperature with stirring and additional stirring overnight, the crystals formed are aspirated. The crystallizate is washed first with 8 ml of water (1-6 ° C) and then twice with 20 ml of acetone each.
Sušením v sušičke s núteným obehom vzduchu (najskôr pri teplote miestnosti, neskoršie pri teplote 50 až 60’C) sa získaDrying in a forced-air dryer (first at room temperature, later at 50 to 60'C) yields
32,58 g vínanu (80,02 % teórie).32.58 g of tartrate (80.02% of theory).
Príklad 4Example 4
Predloží sa 150 ml vody a 50 ml izopropanolu. Pridá sa150 ml of water and 50 ml of isopropanol are introduced. Add
39,8 g (0,21 mol) L-( + )-vínnej kyseliny a 50 g (0,21 mol) R,Sketamínu. Zmes sa za miešania zahrievaním udržuje na teplote spätného toku až do získania roztoku (prípadne sa pridá voda až do dokonalého rozpustenia).39.8 g (0.21 mol) of L- (+) - tartaric acid and 50 g (0.21 mol) of R, Sketamine. The mixture is heated to reflux with stirring until heating (or water is added until complete dissolution).
Po ochladení na teplotu miestnosti za miešania a dodatočnom miešaní cez noc sa vytvorené kryštály odsajú. Odsiate kryštály sa premyjú 20 ml zmesi 1:2 voda/izopropanol a sušia sa v sušičke s núteným obehom vzduchu (najskôr pri teplote miestnosti, neskoršie pri teplote 50 až 60’C), čím sa získa 24,45 g vínanu (62,63 % teórie).After cooling to room temperature with stirring and additional stirring overnight, the crystals formed are aspirated. The aspirated crystals were washed with 20 ml of 1: 2 water / isopropanol and dried in a forced-air dryer (first at room temperature, later at 50-60 ° C) to obtain 24.45 g of tartrate (62.63). % of theory).
Príklad 5Example 5
Rozpustí sa 50 g (0,21 mol) R,S-ketamínu za teploty varu v 300 ml acetónu a zmieša sa s 31,5 g (0,21 mol) L-( + )-vínnej kyseliny a 100 ml vody. Zmes ako celok sa za miešania nechá vychladnúť a prípadne sa naočkuje.Dissolve 50 g (0.21 mol) of R, S-ketamine at boiling point in 300 ml of acetone and mix with 31.5 g (0.21 mol) of L- (+) - tartaric acid and 100 ml of water. The mixture as a whole is allowed to cool with stirring and optionally seeded.
Nechá sa stáť cez noc, vytvorené kryštály sa odsajú, dvakrát sa premyjú 20 ml acetónu a sušia sa v sušičke s núteným obehom vzduchu (najskôr pri teplote miestnosti, neskoršie pri teplote 50 až 60’C). Získa sa 30,30 g vínanu (74,57 % teórie),After standing overnight, the crystals formed are aspirated, washed twice with 20 ml of acetone and dried in a forced-air dryer (first at room temperature, later at 50-60 ° C). 30.30 g of tartrate (74.57% of theory) are obtained,
Príklad 6Example 6
Predloží sa 75 ml vody a 50 ml izopropanolu. Pridá sa75 ml of water and 50 ml of isopropanol are introduced. Add
39,8 g (0,27 mol) L-( + )-vínnej kyseliny. Zmes sa za miešania zahrievaním udržuje na teplote spätného toku až do získania číreho roztoku.39.8 g (0.27 mol) of L- (+) - tartaric acid. The mixture was heated to reflux with stirring until a clear solution was obtained.
Po ochladení na teplotu miestnosti za miešania a dodatočnom miešaní cez noc sa vytvorené kryštály odsajú. Kryštalizát sa premyje 20 ml zmesi 1:2 voda/izopropanol a suší sa v sušičke s núteným obehom vzduchu (najskôr pri teplote miestnosti, neskoršie pri teplote 50 až 60°C), čím sa získa 34,84 g vínanu (85,74 % teórie).After cooling to room temperature with stirring and additional stirring overnight, the crystals formed are aspirated. The crystallizate is washed with 20 ml of 1: 2 water / isopropanol and dried in a forced-air dryer (first at room temperature, later at 50-60 ° C) to give 34.84 g of tartrate (85.74%). theory).
Príklad 7Example 7
Rozpustí sa 20 g spôsobom podľa príkladu 4 získaného S-( + )vínanu v 100 ml vody pri teplote 30 až 40’C. Približne 7 ml 50% roztoku hydroxidu sodného sa vyzráža S-(-) -ketamín vo forme zásady až pri hodnote pH približne 13. Zásada sa odsaje a premyje sa vodou až do neutrálnej hodnoty pH 7 až 8. Suší sa v sušičke s núteným obehom vzduchu počas približne 24 hodín pri teplote 50’C. Získa sa 11,93 g S-(-)-ketamínu (97,79 % teórie).Dissolve 20 g of the S- (+) tartrate obtained according to Example 4 in 100 ml of water at 30 to 40 ° C. Approximately 7 ml of 50% sodium hydroxide solution precipitates S - (-) ketamine as a base at a pH of approximately 13. The base is aspirated and washed with water to a neutral pH of 7-8. Dry in a forced-air dryer 24 hours at 50 ° C. 11.93 g of S - (-) - ketamine (97.79% of theory) are obtained.
Príklad 8Example 8
Rozpustí sa 5 g spôsobom podľa príkladu 7 získaného S(-)-ketamínu v 50 ml izopropanolu pri teplote približne 50’C a prípadne sa odsaje cez kremelinu. Pri teplote 50 až 60’C sa zavádza plynný chlorovodík až do dosiahnutia hodnoty pH 0 ažDissolve 5 g of the S (-) - ketamine obtained according to Example 7 in 50 ml of isopropanol at a temperature of approximately 50 ° C and suction if necessary through kieselguhr. Hydrogen chloride gas is introduced at a temperature of 50-60 ° C until a pH of 0 to 60 is reached
1. Nechá sa ochladiť na teplotu miestnosti. Produkt sa odsaje a premyje sa približne 5 ml izopropanolu. Vlhký produkt sa suší v sušičke s núteným obehom vzduchu cez noc pri teplote približne 50’C. Získa sa 5,09 g S-( + )-ketamínhydrochloridu (88,06 % teórie).1. Allow to cool to room temperature. The product is filtered off with suction and washed with approximately 5 ml of isopropanol. The wet product is dried in a forced-air dryer at about 50 ° C overnight. 5.09 g of S- (+) -ketamine hydrochloride are obtained (88.06% of theory).
Priemyslová využiteľnosť:Industrial usability:
Spôsob štiepenia racemického 2-(o-chlórfenyl)-2-metylaminocyklohexanónu pri použití enentiomérnej formy kyseliny vínnej a ako rozpúšťadla vody alebo zmesi vody a alkoholu a/alebo ketónu, éteru alebo esteru.Process for resolution of racemic 2- (o-chlorophenyl) -2-methylaminocyclohexanone using an enantiomeric form of tartaric acid and as a solvent of water or a mixture of water and an alcohol and / or ketone, ether or ester.
Claims (12)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19619665A DE19619665C2 (en) | 1996-05-15 | 1996-05-15 | Racemate separation of ketamine |
| PCT/EP1997/002360 WO1997043244A1 (en) | 1996-05-15 | 1997-05-07 | Racemic separation of ketamine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| SK152998A3 true SK152998A3 (en) | 1999-07-12 |
| SK282699B6 SK282699B6 (en) | 2002-11-06 |
Family
ID=7794445
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK1529-98A SK282699B6 (en) | 1996-05-15 | 1997-05-07 | Separation method of racemic 2-(o-chlorophenyl)-2-methylaminocycl ohexanone |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US6040479A (en) |
| EP (1) | EP0918744B1 (en) |
| JP (1) | JP4151988B2 (en) |
| AT (1) | ATE272606T1 (en) |
| AU (1) | AU727528B2 (en) |
| CA (1) | CA2253575C (en) |
| CZ (1) | CZ293546B6 (en) |
| DE (2) | DE19619665C2 (en) |
| DK (1) | DK0918744T3 (en) |
| EE (1) | EE03436B1 (en) |
| ES (1) | ES2224247T3 (en) |
| HU (1) | HU225773B1 (en) |
| IL (1) | IL127026A (en) |
| NO (1) | NO311565B1 (en) |
| PL (1) | PL187625B1 (en) |
| PT (1) | PT918744E (en) |
| SK (1) | SK282699B6 (en) |
| TR (1) | TR199802317T2 (en) |
| WO (1) | WO1997043244A1 (en) |
| ZA (1) | ZA974216B (en) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0002693B8 (en) * | 2000-06-19 | 2021-05-25 | Cristalia Produtos Quim Farmaceuticos Ltda | process for obtaining the enantiomers of ketamine and its pharmaceutically acceptable salts |
| PE20200404A1 (en) | 2013-03-15 | 2020-02-26 | Janssen Pharmaceutica Nv | PHARMACEUTICAL COMPOSITION OF S-KETAMINE HYDROCHLORIDE |
| DK3043785T3 (en) | 2013-09-13 | 2021-11-15 | Univ Chiba Nat Univ Corp | USE OF R-KETAMIN AND SALTS THEREOF AS MEDICINES |
| MX2017001908A (en) | 2014-08-13 | 2017-08-08 | Janssen Pharmaceutica Nv | Method for the treatment of depression. |
| CA2961208A1 (en) | 2014-09-15 | 2016-03-24 | Janssen Pharmaceutica Nv | Val66met (snp rs6265) genotype specific dosing regimens and methods for the treatment of depression |
| US20160332962A1 (en) * | 2015-05-13 | 2016-11-17 | Janssen Pharmaceutica Nv | (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine |
| CN110167541A (en) | 2016-10-27 | 2019-08-23 | 国立大学法人千叶大学 | (S) application of-Norketamine and its salt as drug |
| US20200009081A1 (en) | 2017-09-13 | 2020-01-09 | Janssen Pharmaceutica N.V. | Delivery Of Esketamine For The Treatment Of Depression |
| US20200405663A1 (en) | 2017-09-27 | 2020-12-31 | National University Corporation Chiba University | R-ketamine and derivative thereof as prophylactic or therapeutic agent for neurodegeneration disease or recognition functional disorder |
| CN117531017A (en) | 2017-12-22 | 2024-02-09 | 詹森药业有限公司 | Esketamine for treating depression |
| BR112020016500A2 (en) | 2018-02-15 | 2020-12-15 | National University Corporation Chiba University | PREVENTIVE OR THERAPEUTIC AGENT AND PHARMACEUTICAL COMPOSITION FOR INFLAMMATORY DISEASE OR BONE DISEASE |
| AU2019262197A1 (en) | 2018-05-04 | 2020-11-26 | Perception Neuroscience, Inc. | Methods of treating substance abuse |
| JP7483630B2 (en) | 2018-12-27 | 2024-05-15 | 国立大学法人千葉大学 | R-Ketamine and its derivatives as preventive or therapeutic agents for neurodevelopmental disorders |
| MA55218A (en) | 2019-03-05 | 2022-01-12 | Janssen Pharmaceuticals Inc | ESKETAMINE FOR THE TREATMENT OF DEPRESSION |
| US20220220062A1 (en) * | 2019-04-16 | 2022-07-14 | Janssen Pharmaceutica Nv | Synthetic methods of preparing esketamine |
| CN112125816A (en) * | 2020-03-17 | 2020-12-25 | 国药集团工业有限公司 | Racemization method of ketamine, its derivative or its salt |
| CN112409195A (en) * | 2020-03-17 | 2021-02-26 | 国药集团工业有限公司 | Preparation method of (S) -ketamine hydrochloride, intermediate and crystal form thereof |
| WO2024145288A2 (en) * | 2022-12-28 | 2024-07-04 | Perception Neuroscience, Inc. | Methods of administering r-ketamine |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH535201A (en) * | 1969-12-19 | 1973-03-31 | Bristol Myers Co | Process for the resolution of racemic 2- (o-chlorophenyl) -2-methylaminocyclohexanone into the optically active isomers |
-
1996
- 1996-05-15 DE DE19619665A patent/DE19619665C2/en not_active Expired - Lifetime
-
1997
- 1997-05-07 TR TR1998/02317T patent/TR199802317T2/en unknown
- 1997-05-07 EP EP97923022A patent/EP0918744B1/en not_active Expired - Lifetime
- 1997-05-07 AT AT97923022T patent/ATE272606T1/en active
- 1997-05-07 CZ CZ19983558A patent/CZ293546B6/en not_active IP Right Cessation
- 1997-05-07 US US09/180,530 patent/US6040479A/en not_active Expired - Lifetime
- 1997-05-07 JP JP54048797A patent/JP4151988B2/en not_active Expired - Lifetime
- 1997-05-07 CA CA002253575A patent/CA2253575C/en not_active Expired - Lifetime
- 1997-05-07 EE EE9800394A patent/EE03436B1/en unknown
- 1997-05-07 SK SK1529-98A patent/SK282699B6/en not_active IP Right Cessation
- 1997-05-07 PT PT97923022T patent/PT918744E/en unknown
- 1997-05-07 IL IL12702697A patent/IL127026A/en not_active IP Right Cessation
- 1997-05-07 DE DE59711834T patent/DE59711834D1/en not_active Expired - Lifetime
- 1997-05-07 ES ES97923022T patent/ES2224247T3/en not_active Expired - Lifetime
- 1997-05-07 WO PCT/EP1997/002360 patent/WO1997043244A1/en active IP Right Grant
- 1997-05-07 AU AU28943/97A patent/AU727528B2/en not_active Expired
- 1997-05-07 PL PL97329743A patent/PL187625B1/en unknown
- 1997-05-07 DK DK97923022T patent/DK0918744T3/en active
- 1997-05-07 HU HU9903085A patent/HU225773B1/en unknown
- 1997-05-15 ZA ZA9704216A patent/ZA974216B/en unknown
-
1998
- 1998-11-13 NO NO19985300A patent/NO311565B1/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| JP4151988B2 (en) | 2008-09-17 |
| DE59711834D1 (en) | 2004-09-09 |
| HU225773B1 (en) | 2007-08-28 |
| NO311565B1 (en) | 2001-12-10 |
| ATE272606T1 (en) | 2004-08-15 |
| EE03436B1 (en) | 2001-06-15 |
| NO985300L (en) | 1998-11-13 |
| CA2253575A1 (en) | 1997-11-20 |
| SK282699B6 (en) | 2002-11-06 |
| DE19619665A1 (en) | 1997-11-20 |
| EE9800394A (en) | 1999-06-15 |
| IL127026A0 (en) | 1999-09-22 |
| CZ355898A3 (en) | 1999-04-14 |
| PL187625B1 (en) | 2004-08-31 |
| EP0918744A1 (en) | 1999-06-02 |
| CZ293546B6 (en) | 2004-06-16 |
| PL329743A1 (en) | 1999-04-12 |
| HUP9903085A1 (en) | 2000-04-28 |
| ES2224247T3 (en) | 2005-03-01 |
| AU2894397A (en) | 1997-12-05 |
| DK0918744T3 (en) | 2004-12-06 |
| CA2253575C (en) | 2005-11-29 |
| DE19619665C2 (en) | 2001-03-08 |
| US6040479A (en) | 2000-03-21 |
| WO1997043244A1 (en) | 1997-11-20 |
| IL127026A (en) | 2004-02-19 |
| ZA974216B (en) | 1997-12-10 |
| AU727528B2 (en) | 2000-12-14 |
| EP0918744B1 (en) | 2004-08-04 |
| PT918744E (en) | 2004-10-29 |
| TR199802317T2 (en) | 1999-02-22 |
| HUP9903085A3 (en) | 2000-05-29 |
| JP2000510135A (en) | 2000-08-08 |
| NO985300D0 (en) | 1998-11-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SK152998A3 (en) | Racemic separation of ketamine | |
| JP2009521402A (en) | Method for the separation of propargylated aminoindan | |
| CZ292579B6 (en) | Process for preparing pure enantiomers of tropic acid esters | |
| IL181464A (en) | Method for preparing irbesartan and intermediates thereof | |
| JP2011503122A (en) | Separation of 4,5-dimethoxy-1- (methylaminomethyl) -benzocyclobutane | |
| PL212886B1 (en) | Method of obtaining 11-amino-3-chloro-6,11-dihydro-5,5-dioxo-6-methyl-dibenzo[c,f]thiazepine and application thereof in thianeptin synthesising process | |
| US4968837A (en) | Resolution of racemic mixtures | |
| KR20120090940A (en) | Process for preparing levosimendan and intermediates for use in the process | |
| SK151297A3 (en) | New process for the preparation of ropivacaine hydrochloride monohydrate | |
| JP2546624B2 (en) | Process for producing optically pure amino alcohol | |
| WO2014009964A1 (en) | Process for enantiomeric enrichment of 2 ', 6 ' - pipecoloxylidide | |
| WO2016046833A2 (en) | Improved processes for the preparation of agomelatine using novel intermediates | |
| KR100275978B1 (en) | Process for the preparation of n-methyl-n(4-(4-phenyl-4acetylaminopiperidine-1-yl)-2-(3,4-dichlorophenyl)butyl)benzamide | |
| JP3005669B2 (en) | Method for producing asymmetric fluorinated primary amines | |
| US4831167A (en) | Process for diastereoselective reduction of 3-amino-1-benzoxepin-5(2H)-ones | |
| EP3292102B1 (en) | Isoindolinones, processes for the production of chiral derivatives thereof and use thereof | |
| EP0916657B9 (en) | 1-phenylpyrrolidone derivatives having optical activity | |
| JP2852023B2 (en) | Method for producing 2-fluorocyclopropylamine sulfonate and its chemical compound 2-fluorocyclopropyl isocyanate | |
| CA2409614C (en) | Separation of the enantiomers of piperidone derivatives with simultaneous racemisation in situ of the unwanted enantiomer | |
| EP1484315A1 (en) | Process for production of optically active beta-phenylalanine | |
| EA026170B1 (en) | Process for the manufacture of ivabradine and of intermediates of synthesis thereof | |
| WO2009068284A2 (en) | Process for the stereoselective reduction of ketoimines catalysed by trichlorosilane | |
| JPS6327348B2 (en) | ||
| SK434289A3 (en) | Method for resolving izomers with aim to attain (e)-n-methyl-6,6- -dimethyl-n-(1-naphthylmethyl)-hept-2-en-4-in-1-yl amine | |
| WO1996035660A1 (en) | Synthesis of optically active aminoindanol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK4A | Expiry of patent |
Expiry date: 20170507 |